← All trials
NCT06309992
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 13, 2024
- Primary completion
- Feb 16, 2026
- Completion date
- Mar 9, 2026
- First posted
- Mar 13, 2024
- Last posted
- Oct 1, 2024
- Enrollment
- 160
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Boehringer IngelheimLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.